The Perpetual 'Affordability' Charade
FIRST INSTANCE: The Faustian Bargain is Struck The argument that robust patent protection and unimpeded pricing power are essential for pharmaceutical innovation has been a cornerstone of industry lobbying since at least the 1980s. The 1984 Hatch-Waxman Act, while intended to balance innovation with generic competition, significantly bolstered patent extensions and market exclusivity for
brand-name drugs. This effectively codified the industry's ability to charge exorbitant prices for extended periods, arguing it was necessary to recoup research and development (R&D) costs. Curiously, that never seems to translate to lower prices once those R&D costs are, hypothetically, covered. REPETITIONS: The Echo Chamber of 'Concerns' Mid-1990s: As drug prices soared, particularly for new
HIV/AIDS medications, the industry trotted out the same line. "Price controls stifle innovation!" they cried, even as significant public funds (through NIH, for example) contributed to much of the foundational research. 2003: The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) was passed, notably prohibiting Medicare from negotiating drug prices directly, a glaring carve-out
that continues to cost taxpayers billions. The industry's argument? Free market competition would handle it. Apparently, 20 years later, that 'free market' is still on extended lunch break. 22 Years and Counting (2002-Present): Much like Netanyahu government officials claiming Iran is "months from a nuke," the pharmaceutical industry has consistently warned that any attempt to rein in prices would